サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1421811

オンコロジーコンパニオン診断市場、シェア、規模、動向、産業分析レポート：提供別、技術別、疾患タイプ別、エンドユーザー別、地域別、セグメント別予測、2023年～2032年

Oncology Companion Diagnostic Market Share, Size, Trends, Industry Analysis Report, By Offering (Product, Services); By Technology; By Disease Type; By End User; By Region; Segment Forecast, 2023- 2032

出版日
ページ情報
英文 114 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
オンコロジーコンパニオン診断市場、シェア、規模、動向、産業分析レポート：提供別、技術別、疾患タイプ別、エンドユーザー別、地域別、セグメント別予測、2023年～2032年
出版日: 2023年12月23日
発行: Polaris Market Research
ページ情報: 英文 114 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のオンコロジーコンパニオン診断市場規模は2032年までに105億7,000万米ドルに達する見込みです。本レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

患者中心のヘルスケアへのシフトは、コンパニオン診断に有利な環境を作り出しています。これらのツールは、ヘルスケアプロバイダーがオーダーメイドの治療計画を立案し、副作用を最小限に抑え、患者の転帰を最適化することを可能にします。このような患者中心のアプローチは、ヘルスケアの現場でますます評価されるようになっています。患者の間でコンパニオン診断薬に対する認識が高まっていることは、導入拡大の好機です。患者を治療に関与させ、これらの診断の利点に関する情報を患者に提供することは、市場の成長を促進します。

コンパニオン診断薬は、より費用対効果の高いヘルスケアへの道を提供します。効果のない治療法の使用を減らし、入院や合併症の発生を最小限に抑えることで、これらのツールはヘルスケアコストの抑制に貢献します。同市場は、様々ながん種に関連する新たなバイオマーカーや遺伝子マーカーの発見を目指した継続的な研究努力から利益を得ています。これらの発見によりコンパニオン診断薬の用途が拡大し、市場成長の新たな機会がもたらされます。

新興国には大きな成長機会があります。これらの地域ではヘルスケアのインフラが整備され、認知度が向上しているため、コンパニオン診断薬の採用が大幅に増加する見込みです。ヘルスケアにおける遠隔医療や遠隔診断の拡大は、コンパニオン診断検査へのアクセスを向上させる機会を提供します。この動向は、特に医療が行き届いていない地域や遠隔地に関連するものであり、市場の裾野を広げるものです。

リキッドバイオプシーや次世代シーケンサーを含む診断技術の革新は、より正確で包括的なコンパニオン診断の機会を提供します。これらの技術革新は、診断精度の向上と検査能力の拡大につながります。

オンコロジーコンパニオン診断市場レポートハイライト

がん罹患率の増加、世界の高齢化、精密医療の進展により、2022年には製品分野が大きなシェアを占める

免疫組織化学は、バイオマーカー検出、サブタイプ分類、治療ガイダンスに広く使用されていることから、最大セグメントとして浮上しました。

乳がん分野は予測期間中に大幅な成長が見込まれるが、これは主に標的療法の採用拡大や規制当局の支援によるものです。

主に早期発見・診断、治療モニタリング、患者中心のケアにより、病院セグメントが2022年の市場収益シェアで最大を占める

北米地域は、個別化医療の台頭、規制の枠組み、パートナーシップや共同研究により、2022年の市場シェアの大半を占めました。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のオンコロジーコンパニオン診断市場に関する洞察

  • オンコロジーコンパニオン診断-業界スナップショット
  • オンコロジーコンパニオン診断市場力学
    • 促進要因と機会
      • がん症例の増加、がん標的療法の利用可能性の拡大、精密医療の進歩
      • 個別化医療への注目の高まり
    • 抑制要因と課題
      • 規制上の課題と承認プロセス
  • PESTLE分析
  • オンコロジーコンパニオン診断業界の動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界のオンコロジーコンパニオン診断市場、技術別

  • 主な調査結果
  • イントロダクション
  • 免疫組織化学
  • 次世代シーケンス
  • ポリメラーゼ連鎖反応
  • その他

第6章 世界のオンコロジーコンパニオン診断市場、提供別

  • 主な調査結果
  • イントロダクション
  • 製品
  • サービス

第7章 世界のオンコロジーコンパニオン診断市場、疾患タイプ別

  • 主な調査結果
  • イントロダクション
  • 黒色腫
  • 乳がん
  • 結腸直腸がん
  • 白血病
  • 前立腺がん
  • その他

第8章 世界のオンコロジーコンパニオン診断市場、エンドユーザー別

  • 主な調査結果
  • イントロダクション
  • 病院
  • 診断研究所
  • その他

第9章 世界のオンコロジーコンパニオン診断市場、地域別

  • 主な調査結果
  • イントロダクション
    • オンコロジーコンパニオン診断市場評価、地域、2019-2032年
  • オンコロジーコンパニオン診断市場-北米
    • 北米：オンコロジーコンパニオン診断市場、技術別、2019-2032年
    • 北米：オンコロジーコンパニオン診断市場、エンドユーザー別、2019～2032年
    • 北米：オンコロジーコンパニオン診断市場、提供別、2019～2032年
    • 北米：オンコロジーコンパニオン診断市場、疾患タイプ別、2019～2032年
    • オンコロジーコンパニオン診断市場-米国
    • オンコロジーコンパニオン診断市場- カナダ
  • オンコロジーコンパニオン診断市場- 欧州
    • 欧州：オンコロジーコンパニオン診断市場、技術別、2019～2032年
    • 欧州：オンコロジーコンパニオン診断市場、エンドユーザー別、2019～2032年
    • 欧州：オンコロジーコンパニオン診断市場、提供別、2019～2032年
    • 欧州：オンコロジーコンパニオン診断市場、疾患タイプ別、2019～2032年
    • オンコロジーコンパニオン診断市場- 英国
    • オンコロジーコンパニオン診断市場- フランス
    • オンコロジーコンパニオン診断市場- ドイツ
    • オンコロジーコンパニオン診断市場- イタリア
    • オンコロジーコンパニオン診断市場- スペイン
    • オンコロジーコンパニオン診断市場- オランダ
    • オンコロジーコンパニオン診断市場- ロシア
  • オンコロジーコンパニオン診断市場- アジア太平洋
    • アジア太平洋：オンコロジーコンパニオン診断市場、技術別、2019～2032年
    • アジア太平洋：オンコロジーコンパニオン診断市場、エンドユーザー別、2019～2032年
    • アジア太平洋：オンコロジーコンパニオン診断市場、提供別、2019～2032年
    • アジア太平洋：オンコロジーコンパニオン診断市場、疾患タイプ別、2019～2032年
    • オンコロジーコンパニオン診断市場- 中国
    • オンコロジーコンパニオン診断市場- インド
    • オンコロジーコンパニオン診断市場- 日本
    • オンコロジーコンパニオン診断市場- マレーシア
    • オンコロジーコンパニオン診断市場- インドネシア
    • オンコロジーコンパニオン診断市場- 韓国
  • オンコロジーコンパニオン診断市場-中東およびアフリカ
    • 中東およびアフリカ：オンコロジーコンパニオン診断市場、技術別、2019～2032年
    • 中東およびアフリカ：オンコロジーコンパニオン診断市場、エンドユーザー別、2019～2032年
    • 中東およびアフリカ：オンコロジーコンパニオン診断市場、提供別、2019～2032年
    • 中東およびアフリカ：オンコロジーコンパニオン診断市場、疾患タイプ別、2019～2032年
    • オンコロジーコンパニオン診断市場- サウジアラビア
    • オンコロジーコンパニオン診断市場- 南アフリカ
    • オンコロジーコンパニオン診断市場- イスラエル
    • オンコロジーコンパニオン診断市場-UAE
  • オンコロジーコンパニオン診断市場-ラテンアメリカ
    • ラテンアメリカ：オンコロジーコンパニオン診断市場、技術別、2019-2032年
    • ラテンアメリカ：オンコロジーコンパニオン診断市場、エンドユーザー別、2019～2032年
    • ラテンアメリカ：オンコロジーコンパニオン診断市場、提供別、2019～2032年
    • ラテンアメリカ：オンコロジーコンパニオン診断市場、疾患タイプ別、2019～2032年
    • オンコロジーコンパニオン診断市場- メキシコ
    • オンコロジーコンパニオン診断市場- ブラジル
    • オンコロジーコンパニオン診断市場- アルゼンチン

第10章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第11章 企業プロファイル

  • Abbott Laboratories
  • Agilent Technologies
  • Bio-Rad Laboratories
  • Biocartis
  • Exact Sciences
  • Genedrive
  • Genomic Health
  • Guardant Health
  • Illumina
  • Invivoscribe
  • Myriad Genetics
  • QIAGEN
  • Roche Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific
図表

List of Tables

  • Table 1 Global Oncology Companion Diagnostic Market, by Technology, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Oncology Companion Diagnostic Market, by Offering, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Oncology Companion Diagnostic Market, by Disease type, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Oncology Companion Diagnostic Market, by End User, by Region, 2019-2032 (USD Billion)
  • Table 5 Oncology Companion Diagnostic Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 7 North America: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 8 North America: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 9 North America: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 10 U.S.: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 11 U.S.: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 12 U.S.: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 13 U.S.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 14 Canada: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 15 Canada: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 16 Canada: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 17 Canada: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 18 Europe: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 19 Europe: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 20 Europe: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 21 Europe: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 22 Germany: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 23 Germany: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 24 Germany: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 25 Germany: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 26 France: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 27 France: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 28 France: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 29 France: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 30 UK: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 31 UK: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 32 UK: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 33 UK: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 34 Italy: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 35 Italy: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 36 Italy: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 37 Italy: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 42 Spain: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 43 Spain: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 44 Spain: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 45 Spain: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 46 Russia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 47 Russia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 48 Russia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 49 Russia: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 54 China: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 55 China: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 56 China: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 57 China: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 58 Japan: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 59 Japan: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 60 Japan: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 61 Japan: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 62 India: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 63 India: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 64 India: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 65 India: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 74 South Korea: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 75 South Korea: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 76 South Korea: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 77 South Korea: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 78 Latin America: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 79 Latin America: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 80 Latin America: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 81 Latin America: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 82 Brazil: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 83 Brazil: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 84 Brazil: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 85 Brazil: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 86 Mexico: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 87 Mexico: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 88 Mexico: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 89 Mexico: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 90 Argentina: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 91 Argentina: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 92 Argentina: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 93 Argentina: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 98 UAE: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 99 UAE: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 100 UAE: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 101 UAE: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 106 South Africa: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 107 South Africa: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 108 South Africa: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 109 South Africa: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • Table 110 Israel: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • Table 111 Israel: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • Table 112 Israel: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • Table 113 Israel: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Oncology Companion Diagnostic Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up End User
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Technology
  • Figure 7. Global Oncology Companion Diagnostic Market, by Technology, 2021 & 2030 (USD Billion)
  • Figure 8. Market by End User
  • Figure 9. Global Oncology Companion Diagnostic Market, by End User, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Offering
  • Figure 11. Global Oncology Companion Diagnostic Market, by Offering, 2021 & 2030 (USD Billion)
  • Figure 12. Market by Disease type
  • Figure 13. Global Oncology Companion Diagnostic Market, by Disease type, 2021 & 2030 (USD Billion)
目次
Product Code: PM4133

The global oncology companion diagnostic market size is expected to reach USD 10.57 billion by 2032, according to a new study by Polaris Market Research. The report "Oncology Companion Diagnostic Market Share, Size, Trends, Industry Analysis Report, By Offering (Product, Services); By Technology; By Disease Type; By End User; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The shift towards patient-centered healthcare has created a favorable environment for companion diagnostics. These tools enable healthcare providers to design tailored treatment plans, minimizing side effects and optimizing patient outcomes. This patient-centric approach is increasingly valued in the healthcare landscape. The rising awareness of companion diagnostics among patients provides an opportunity for increased adoption. Engaging patients in their care and empowering them with information about the benefits of these diagnostics drives market growth.

Companion diagnostics offer a route to more cost-effective healthcare. By reducing the use of ineffective therapies and minimizing the occurrence of hospitalizations and complications, these tools contribute to healthcare cost containment. The market benefits from ongoing research efforts aimed at discovering new biomarkers and genetic markers associated with various cancer types. These discoveries expand the applications of companion diagnostics, opening up new opportunities for market growth.

Emerging economies offer a significant growth opportunity. As these regions improve healthcare infrastructure and increase awareness, the adoption of companion diagnostics is poised for substantial growth. The expansion of telemedicine and remote diagnostics in healthcare presents opportunities to increase access to companion diagnostic testing. This trend, particularly relevant in underserved or remote areas, broadens the market's reach.

The ongoing innovations in diagnostic technologies, including liquid biopsies and next-generation sequencing, present opportunities for more accurate and comprehensive companion diagnostics. These innovations can lead to greater diagnostic precision and expanded testing capabilities.

Oncology Companion Diagnostic Market Report Highlights

Product segment held a significant share in 2022, owing to growing cancer prevalence, global aging population, and advancements in precision medicine

Immunohistochemistry emerged as the largest segment on account of its wide use in biomarker detection, subtype classification, and treatment guidance

The breast cancer segment is expected to experience significant growth during the forecast period, which is mainly driven by its growing adoption of targeted therapies and regulatory support

Hospitals segment held the maximum market revenue share in 2022, mainly for early detection and diagnosis, treatment monitoring, and patient-centric care

North America region dominated the market with majority share in 2022, owing to the rise of personalized medicine, regulatory framework, and partnerships and collaborations

The global key market players include: Abbott Laboratories, Agilent Technologies, Illumina, Invivoscribe, Roche Diagnostics, Sysmex Corporation, and Thermo Fisher Scientific, among others

Polaris Market Research has segmented the Oncology Companion Diagnostic market report based on offering, technology, disease type, end user, and region:

Oncology Companion Diagnostic, Offering Outlook (Revenue - USD Billion, 2019 - 2032)

  • Product
  • Services

Oncology Companion Diagnostic, Technology Outlook (Revenue - USD Billion, 2019 - 2032)

  • Immunohistochemistry
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Others

Oncology Companion Diagnostic, Disease Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Melanoma
  • Breast Cancer
  • Colorectal Cancer
  • Leukaemia
  • Prostate Cancer
  • Others

Oncology Companion Diagnostic, End User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals
  • Diagnostic Labs
  • Others

Oncology Companion Diagnostic, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Oncology Companion Diagnostic Market Insights

  • 4.1. Oncology Companion Diagnostic - Industry Snapshot
  • 4.2. Oncology Companion Diagnostic Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising cancer cases, growing availability of targeted cancer therapies, and precision medicine advancements
      • 4.2.1.2. Growing emphasis on personalized medicine
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Regulatory challenges and approval processes
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Oncology Companion Diagnostic Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Oncology Companion Diagnostic Market, by Technology

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
  • 5.3. Immunohistochemistry
    • 5.3.1. Global Oncology Companion Diagnostic Market, by Immunohistochemistry, by Region, 2019-2032 (USD Billion)
  • 5.4. Next-Generation Sequencing
    • 5.4.1. Global Oncology Companion Diagnostic Market, by Next-Generation Sequencing, by Region, 2019-2032 (USD Billion)
  • 5.5. Polymerase Chain Reaction
    • 5.5.1. Global Oncology Companion Diagnostic Market, by Polymerase Chain Reaction, by Region, 2019-2032 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global Oncology Companion Diagnostic Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Oncology Companion Diagnostic Market, by Offering

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
  • 6.3. Product
    • 6.3.1. Global Oncology Companion Diagnostic Market, by Product, by Region, 2019-2032 (USD Billion)
  • 6.4. Services
    • 6.4.1. Global Oncology Companion Diagnostic Market, by Services, by Region, 2019-2032 (USD Billion)

7. Global Oncology Companion Diagnostic Market, by Disease Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Oncology Companion Diagnostic Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.3. Melanoma
    • 7.3.1. Global Oncology Companion Diagnostic Market, by Melanoma, by Region, 2019-2032 (USD Billion)
  • 7.4. Breast Cancer
    • 7.4.1. Global Oncology Companion Diagnostic Market, by Breast Cancer, by Region, 2019-2032 (USD Billion)
  • 7.5. Colorectal Cancer
    • 7.5.1. Global Oncology Companion Diagnostic Market, by Colorectal Cancer, by Region, 2019-2032 (USD Billion)
  • 7.6. Leukaemia
    • 7.6.1. Global Oncology Companion Diagnostic Market, by Leukaemia, by Region, 2019-2032 (USD Billion)
  • 7.7. Prostate Cancer
    • 7.7.1. Global Oncology Companion Diagnostic Market, by Prostate Cancer, by Region, 2019-2032 (USD Billion)
  • 7.8. Others
    • 7.8.1. Global Oncology Companion Diagnostic Market, by Others, by Region, 2019-2032 (USD Billion)

8. Global Oncology Companion Diagnostic Market, by End User

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
  • 8.3. Hospitals
    • 8.3.1. Global Oncology Companion Diagnostic Market, by Hospitals, by Region, 2019-2032 (USD Billion)
  • 8.4. Diagnostic Labs
    • 8.4.1. Global Oncology Companion Diagnostic Market, by Diagnostic Labs, by Region, 2019-2032 (USD Billion)
  • 8.5. Others
    • 8.5.1. Global Oncology Companion Diagnostic Market, by Others, by Region, 2019-2032 (USD Billion)

9. Global Oncology Companion Diagnostic Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Oncology Companion Diagnostic Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Oncology Companion Diagnostic Market - North America
    • 9.3.1. North America: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.3.2. North America: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.3.3. North America: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.3.4. North America: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.3.5. Oncology Companion Diagnostic Market - U.S.
      • 9.3.5.1. U.S.: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.3.6. Oncology Companion Diagnostic Market - Canada
      • 9.3.6.1. Canada: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.4. Oncology Companion Diagnostic Market - Europe
    • 9.4.1. Europe: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.4.5. Oncology Companion Diagnostic Market - UK
      • 9.4.5.1. UK: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.4.6. Oncology Companion Diagnostic Market - France
      • 9.4.6.1. France: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.4.7. Oncology Companion Diagnostic Market - Germany
      • 9.4.7.1. Germany: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.4.8. Oncology Companion Diagnostic Market - Italy
      • 9.4.8.1. Italy: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.4.9. Oncology Companion Diagnostic Market - Spain
      • 9.4.9.1. Spain: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.4.10. Oncology Companion Diagnostic Market - Netherlands
      • 9.4.10.1. Netherlands: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.4.11. Oncology Companion Diagnostic Market - Russia
      • 9.4.11.1. Russia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.5. Oncology Companion Diagnostic Market - Asia Pacific
    • 9.5.1. Asia Pacific: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.5.5. Oncology Companion Diagnostic Market - China
      • 9.5.5.1. China: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.5.6. Oncology Companion Diagnostic Market - India
      • 9.5.6.1. India: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.5.7. Oncology Companion Diagnostic Market - Japan
      • 9.5.7.1. Japan: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.5.8. Oncology Companion Diagnostic Market - Malaysia
      • 9.5.8.1. Malaysia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.5.9. Oncology Companion Diagnostic Market - Indonesia
      • 9.5.9.1. Indonesia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.5.10. Oncology Companion Diagnostic Market - South Korea
      • 9.5.10.1. South Korea: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.6. Oncology Companion Diagnostic Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.6.5. Oncology Companion Diagnostic Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.6.6. Oncology Companion Diagnostic Market - South Africa
      • 9.6.6.1. South Africa: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.6.7. Oncology Companion Diagnostic Market - Israel
      • 9.6.7.1. Israel: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.6.8. Oncology Companion Diagnostic Market - UAE
      • 9.6.8.1. UAE: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
  • 9.7. Oncology Companion Diagnostic Market - Latin America
    • 9.7.1. Latin America: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.7.5. Oncology Companion Diagnostic Market - Mexico
      • 9.7.5.1. Mexico: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.7.6. Oncology Companion Diagnostic Market - Brazil
      • 9.7.6.1. Brazil: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)
    • 9.7.7. Oncology Companion Diagnostic Market - Argentina
      • 9.7.7.1. Argentina: Oncology Companion Diagnostic Market, by Technology, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Oncology Companion Diagnostic Market, by End User, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Oncology Companion Diagnostic Market, by Offering, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Oncology Companion Diagnostic Market, by Disease type, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Abbott Laboratories
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Agilent Technologies
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bio-Rad Laboratories
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Biocartis
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Exact Sciences
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Genedrive
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Genomic Health
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Guardant Health
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Illumina
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Invivoscribe
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Myriad Genetics
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. QIAGEN
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Roche Diagnostics
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Sysmex Corporation
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Thermo Fisher Scientific
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development